Type 2 Diabetes – Landscape & Forecast – Disease Landscape & Forecast

The type 2 diabetes (T2D) therapy market is forecast to expand through 2032, supported by polypharmacy and growing use of later-line therapies; however, loss of exclusivity for several key T2D brands like the dipeptidyl peptidase-IV (DPP-IV) inhibitors, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists will exert downward pressure on market sales. Nonetheless, the launch of Eli Lilly’s first-in-class, glucose-dependent insulinotropic polypeptide (GIP) / GLP-1 receptor agonist, Mounjaro, and other late-phase emerging therapies will further support the T2D market through 2032. Although the marketed therapies help maintain HbA1c levels, there is a significant unmet need for disease-modifying therapies that can offer a better quality of life and reduce the treatment burden of intensive combination therapy.

Questions answered

  • What are the drivers and constraints in the T2D market, and how will the market evolve over the forecast period?
  • How has the launch of Eli Lilly’s tirzepatide (Mounjaro) affected the prescribing of GLP-1 receptor agonists such as Eli Lilly’s Trulicity and Novo Nordisk’s Ozempic in the United States? How will the therapy be received in the European market?
  • How will the launch of nonbranded therapies affect the T2D market?
  • What do key opinion leaders think about emerging therapies such as Novo Nordisk’s insulin icodec and CagriSema?

Content highlights

Geographies: United States, EU5, Japan.

Primary research: 19 country-specific interviews with thought-leading endocrinologists and diabetologists. Supported by survey data collected for this and other Clarivate research.

Epidemiology: prevalence of T2D by country with population-specific diagnosed and drug-treatment rates.

Forecast: 10-year, annualized, drug-level sales and patient share of key T2D therapies through 2032, segmented by brands / generics.

Emerging therapies: Phase 3/PR: 5 drugs; coverage of select preclinical, Phase 1, and Phase 2 products.

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents